查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1926898

碘化油注射市场依给药途径、给药频率、包装、用途、最终用户和通路划分－2026-2032年全球预测

Iodized Oil Injection Market by Administration Route, Product Variant, Packaging, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025年碘化油注入市场价值为8,424万美元，预计到2026年将成长至9,606万美元，年复合成长率为12.17%，到2032年将达到1.8826亿美元。

关键市场统计数据
基准年 2025 8424万美元
预计年份：2026年 9606万美元
预测年份 2032 1.8826亿美元
复合年增长率 (%) 12.17%

本文说明了碘化油注射的临床用途、发展历程、安全重点、生产注意事项以及当今的临床意义。

碘化油注射在诊断影像和标靶治疗介入的交叉领域占据着独特的地位，其作用随着影像技术和介入医学的进步而不断演变。碘化油注射最初用作渗透性的造影剂，以增强肝臟和淋巴结构的显影。然而，其药物动力学特性和放射密度特征表明，它不仅可以作为造影剂，还可以作为局部治疗药物的载体。临床医生和供应链相关人员必须了解其临床效用、给药方案、安全性考量和生产规范之间的相互作用，才能指导其应用和采购决策。

重大的技术、监管和物流变革重新定义了碘油输注的临床预期、供应弹性和产品创新。

在技​​术创新、监管调整和服务提供体系转变的推动下，碘油注射领域正发生许多变革，重塑着产业格局。断层扫描和介入影像技术的进步，提高了人们对高解析度造影剂和可预测分布特性的期望，促使人们更加关注产品的纯度、颗粒行为以及与辅助介入设备的兼容性。因此，生产商和临床使用者都在优先考虑能够支援更安全、更精准给药的配方和包装。

评估近期美国关税措施对筹资策略、库存弹性和供应商多元化的累积营运和采购影响

近期关税政策和贸易措施对整个医疗产品供应链产生了连锁反应，影响了采购决策、价格谈判动态和区域製造策略。在此背景下，美国2025年生效的关税政策引入了新的变数，迫使相关人员重新评估采购来源、库存策略和供应商多元化计画。采购团队越来越重视权衡短期成本影响与更近或替代供应来源的策略优势之间的利弊，后者可以降低贸易政策波动带来的风险。

全面的細項分析，阐述了应用、给药途径、最终用户、通路、製剂形式和包装形式的差异如何影响临床应用和商业策略。

将产品开发、商业化和临床实施策略与终端用户的实际需求相匹配，需要对市场区隔动态有深刻的理解。从适应症的角度来看，碘化油注射既可用于诊断，也治疗性介入。诊断应用包括肝臟影像和淋巴影像，而治疗应用则着重于肝臟和淋巴治疗。这种诊断和治疗的双重作用，使得产品配方和包装必须具有独特性，以满足不同的停留时间、渗透性目标和操作要求。

决定关键全球市场部署路径、采购模式和分销选择的区域性营运和监管观点

区域趋势对法规结构、采购行为和临床实践模式有显着影响。相关人员必须考虑地域差异如何影响市场进入和供应链规划。美洲地区面临需求面压力，包括先进介入放射学能力的集中、分散的医院系统以及日益集中化的采购模式（倾向于大规模联合采购协议）。同时，欧洲、中东和非洲地区（EMEA）的监管方式和医疗体系成熟度差异显着，从高度集中的国家采购到分散的私营部门采购，以及对统一安全标准和跨境物流的日益重视，都体现了这一点。

影响碘化油注入供应环境和买家偏好的关键公司策略、生产能力和竞争优势

竞争格局呈现出多元化的特点，既有成熟的专业造影剂生产商，也有正拓展造影剂领域的造影剂生产商，还有提供无菌灌装和包装服务的契约製造。市场参与企业透过配方稳定性、无菌保证、包装创新以及在多种给药途径和临床适应症中供给能力来脱颖而出。那些致力于产生临床证据并进行严格的上市后监测的公司，已在临床医生和采购负责人中建立了牢固的信任，从而推动了产品在医院和门诊机构的应用。

为製造商和经销商提供切实可行的、优先排序的建议，以提高在复杂供应链环境中的生产稳健性、临床实施能力和分销弹性。

产业领导者应采取重点倡议，加强供应连续性，提升临床提案，并加速医疗机构的推广应用。优先投资于无菌生产能力和品管系统，以降低供应风险并满足日益严格的监管要求；同时评估区域製造地，以降低贸易政策风险并缩短关键客户的前置作业时间。此外，还应制定预填充式注射器和管瓶的需求，并支援多剂量和单剂量使用场景，从而简化库存管理和流程。

为了获得可靠的见解，我们采用严格的三角检验调查方法，结合对临床医生和采购负责人的初步访谈、监管审查、文献检验和供应链分析。

本研究采用三角检验法进行综合分析，该方法结合了访谈、监管和临床文献综述以及供应链分析，以确保研究结果的可靠性和可操作性。主要研究包括对临床医生、医院采购负责人、药房主任和供应链经理进行结构化访谈，以了解诊断和治疗应用中的实际使用模式、采购限制和临床偏好。这些定性资料与监管文件和产品标籤进行交叉核对，以检验安全性、给药途径指导和包装限制。

简要概述重点强调了製造品质、临床证据、包装创新和稳健的分销网络等策略重点，以支持产品的持续推广应用。

总之，碘化油注射仍然是一种临床价值高、操作复杂的产品类型，需要不断适应安全性、实证性和供应稳定性的新要求。其在诊断影像和标靶治疗递送方面的双重作用，要求采用专门的配方、包装和给药策略，以满足不同临床环境的需求。先进影像技术的进步、监管力度的加强以及分销模式的改变，共同凸显了稳健的生产规范、区域性商业化策略以及采购中积极主动的风险缓解措施的重要性。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依给药途径分類的碘化油注射市场

  • 肌肉内注射
  • 静脉注射

9. 依剂量数量分類的碘化油注射剂市场

  • 多剂量
  • 单一剂量

10. 依包装类型分類的碘化油注射市场

  • 预填充式注射器
  • 管瓶

第十一章 依应用分類的碘化油注射市场

  • 诊断
    • 肝臟影像
    • 造影
  • 治疗
    • 肝臟治疗
    • 淋巴疗法

第十二章 依最终用户分類的碘化油注射市场

  • 门诊治疗中心
  • 诊所
  • 诊断中心
  • 医院

第十三章 碘化油注射剂市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十四章 碘化油注射剂市场（按地区划分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 碘化油注射市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国碘化油注射剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国碘化油注射剂市场

第十八章：中国碘油注射市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Biophore India Pharmaceuticals Pvt. Ltd.
  • BOC Sciences
  • DVM Global Exports LLP
  • Flagship Biotech International Pvt. Ltd.
  • Fujifilm Toyama Chemical
  • GE Healthcare
  • Glowria Lifecare
  • Guerbet
  • Infinium Pharmachem Limited
  • Jiangsu Hengrui Pharmaceuticals
  • Shanghai Acebright Pharmaceuticals
  • Shanghai Wonder Pharmaceutical
  • Shanghai Zhongxi Sunve Pharmaceutical
  • Teva Pharmaceutical Industries
Product Code: MRR-4F7A6D4FF365

The Iodized Oil Injection Market was valued at USD 84.24 million in 2025 and is projected to grow to USD 96.06 million in 2026, with a CAGR of 12.17%, reaching USD 188.26 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 84.24 million
Estimated Year [2026] USD 96.06 million
Forecast Year [2032] USD 188.26 million
CAGR (%) 12.17%

A detailed introductory overview explaining clinical purpose, evolution, safety priorities, manufacturing considerations, and the operational relevance of iodized oil injection today

Iodized oil injection occupies a distinct niche at the intersection of diagnostic imaging and targeted therapeutic interventions, and its role continues to evolve alongside advances in imaging technology and interventional practice. Historically deployed as a radiopaque medium to enhance visualization of hepatic and lymphatic structures, the formulation's pharmacokinetic properties and radiodensity profile have made it useful both as a contrast agent and as a vehicle for localized therapeutic delivery. Clinicians and supply chain stakeholders alike must understand the interplay between clinical utility, administration paradigms, safety considerations, and manufacturing standards to navigate adoption and procurement decisions.

The clinical landscape is shaped by ongoing refinements in imaging modalities and interventional techniques, which have influenced how iodized oil is selected and administered. Concurrently, regulators and professional societies have emphasized patient safety, product quality, and clear labeling, prompting manufacturers to enhance quality-control measures and to invest in stability and packaging innovations. As a result, the product's relevance today extends beyond simple contrast enhancement, with increasing attention paid to administration route selection, compatibility with adjunct devices and delivery systems, and the procedural training required to optimize both diagnostic yield and therapeutic outcomes. This introduction sets the stage for deeper analysis of market dynamics, segmentation implications, regional variation, and strategic opportunities for stakeholders across the value chain.

Key technological, regulatory, and distribution shifts that are redefining clinical expectations, supply resilience, and product innovation for iodized oil injection

Several transformative shifts are reshaping the landscape for iodized oil injection, driven by technological innovation, regulatory recalibration, and a changing service delivery ecosystem. Advances in cross-sectional and interventional imaging have increased expectations for higher-fidelity contrast agents and more predictable distribution profiles, which in turn has focused attention on product purity, particle behavior, and compatibility with adjunctive interventional devices. As a consequence, manufacturers and clinical users are prioritizing formulations and packaging that support safer, more precise administration.

Regulatory bodies have elevated scrutiny on injectable contrast media and drug-device combinations, concentrating on sterility assurance, extractables and leachables, and post-market surveillance practices. This heightened oversight has prompted both legacy producers and new entrants to strengthen pharmacovigilance processes and to invest in clinical evidence generation. At the same time, distribution models are shifting toward more integrated and digitally enabled channels, including expanded online pharmacy options and centralized procurement within hospital networks, which affects how products are stocked, traced, and replenished. These converging trends are encouraging innovation across product variants and delivery formats while raising the bar for compliance and supply-chain resilience, ultimately changing how clinicians, payers, and procurement teams evaluate iodized oil injection solutions.

Assessing the cumulative operational and procurement consequences of recent United States tariff actions on sourcing strategies, inventory resilience, and supplier diversification

Tariff policies and trade measures introduced in recent years have had ripple effects across medical product supply chains, influencing sourcing decisions, pricing negotiation dynamics, and regional manufacturing strategies. Within this broader context, tariffs implemented in the United States in 2025 have introduced a new variable that compels stakeholders to reassess procurement sourcing, inventory strategies, and supplier diversification plans. Procurement teams are increasingly weighing the trade-offs between near-term cost impacts and the strategic advantages of closer or alternative supply arrangements that can mitigate exposure to trade-policy volatility.

In response, manufacturers and distributors are exploring a range of tactical responses including regional manufacturing adjustments, amendments to contractual incoterms, and enhanced hedging practices in procurement. Clinical users and hospital supply managers are similarly adapting by expanding approved vendor lists, consolidating purchase schedules to minimize transaction costs, and increasing coordination with group purchasing organizations to optimize leverage. While tariffs present short-term operational friction, they are also accelerating conversations about supply-chain transparency, localization of critical packaging and sterile-filling capabilities, and the need for contingency planning to maintain uninterrupted access to essential injectable products. Taken together, these adaptations reflect a sector-wide pivot toward more resilient sourcing and inventory practices that prioritize clinical continuity.

Comprehensive segmentation insights explaining how application, route, end user, distribution, formulation, and packaging distinctions shape clinical adoption and commercial strategy

A nuanced understanding of segmentation dynamics is required to align product development, commercialization, and clinical adoption strategies to the real-world needs of end users. When the market is viewed through the lens of application, iodized oil injection serves both diagnostic purposes and therapeutic interventions: diagnostic applications encompass hepatic imaging and lymphatic imaging, whereas therapeutic uses focus on hepatic treatment and lymphatic treatment. This dual diagnostic-therapeutic role necessitates distinct formulation and packaging considerations to support differing dwell times, radiopacity targets, and procedural handling requirements.

Administration route segmentation highlights the operational and clinical differences between intramuscular and intravenous use, with each route presenting unique requirements for viscosity, injection technique, and post-procedural monitoring. End-user segmentation underscores variable purchasing pathways and usage patterns across ambulatory care centers, clinics, diagnostic centers, and hospitals, each of which has distinct inventory management practices, clinician training profiles, and procurement constraints. Distribution channel segmentation captures the evolving mix between hospital pharmacy, online pharmacy, and retail pharmacy channels, influencing how products are marketed, regulated, and replenished. Product-variant considerations such as multi dose versus single dose formulations affect sterility controls, labeling, and inventory turnover, while packaging segmentation-prefilled syringe versus vial-has direct implications for ease of use in procedural settings, waste management, and compatibility with administration devices. Understanding these interwoven segments helps manufacturers and supply-chain stakeholders prioritize investments in formulation, packaging, and commercial strategy to meet differentiated clinical and operational needs.

Region-specific operational and regulatory perspectives that determine adoption pathways, procurement models, and distribution choices across major global markets

Regional dynamics materially influence regulatory frameworks, procurement behavior, and clinical practice patterns, and stakeholders must consider how geographic variation shapes market access and supply-chain planning. In the Americas, demand-side pressures are informed by concentrated advanced interventional radiology capabilities, distributed hospital systems, and evolving procurement centralization that favors larger group purchasing arrangements. Meanwhile, Europe, Middle East & Africa encompasses a wide spectrum of regulatory approaches and health system maturities, from highly centralized national procurement to fragmented private-sector purchasing, and the region is characterized by a focus on harmonized safety standards and cross-border distribution logistics.

In Asia-Pacific, rapid modernization of tertiary care centers, expanding interventional radiology capacity, and a growing emphasis on domestic manufacturing capabilities drive unique adoption pathways and supplier strategies. Across all regions, differences in reimbursement structures, clinical guidelines, and sterilization and packaging infrastructure influence which product variants and packaging configurations become preferred. Consequently, manufacturers and distributors need region-specific commercialization tactics that align regulatory filings, clinician education, and distribution partnerships with local operational realities, while ensuring that supply continuity and pharmacovigilance commitments meet the expectations of diverse health systems.

Critical corporate strategies, manufacturing capabilities, and competitive differentiators shaping the iodized oil injection supplier landscape and buyer preferences

The competitive landscape is characterized by a mix of established specialty radiopaque product manufacturers, injectable pharmaceutical producers that have expanded into contrast media, and contract manufacturers that provide sterile filling and packaging services. Market participants differentiate on the basis of formulation stability, sterility assurance, packaging innovation, and the ability to supply consistent quality across multiple administration routes and clinical indications. Firms that invest in clinical evidence generation and that maintain rigorous post-market surveillance practices tend to build stronger trust among clinicians and procurement professionals, thereby easing adoption in hospital and ambulatory settings.

Strategic behaviors observed among leading players include vertical integration of sterile manufacturing capabilities, selective licensing agreements to expand geographic reach, and partnerships with distributors that have deep hospital pharmacy relationships. Additionally, innovation efforts focus on improving handling characteristics, reducing risk of contamination, and developing packaging formats that minimize preparation time in procedural suites. Companies that proactively address regulatory compliance, streamline logistics for cold-chain or sterile products, and offer robust training and educational support for clinicians typically gain competitive advantage. These combined factors shape buyer preferences and create barriers to entry for new entrants without demonstrable manufacturing rigor or regulatory track record.

Practical and prioritized recommendations for manufacturers and distributors to enhance manufacturing robustness, clinical adoption, and distribution resilience in a complex supply environment

Industry leaders should pursue targeted actions that strengthen supply continuity, enhance clinical value propositions, and accelerate adoption across care settings. Prioritize investments in sterile manufacturing capacity and quality management systems to reduce supply risk and to meet elevated regulatory expectations, while simultaneously evaluating regional manufacturing footprints to mitigate trade-policy exposure and to shorten lead times for key customers. Complement manufacturing investments with a clear packaging strategy that addresses clinical preferences for prefilled syringes or vials and that supports multi dose and single dose use cases to simplify inventory and procedural workflows.

On the commercial front, develop evidence-generation programs that quantify clinical benefits for both diagnostic and therapeutic applications, and tailor educational initiatives to the needs of hospitals, diagnostic centers, clinics, and ambulatory care centers. Strengthen distribution resilience by diversifying channel partnerships across hospital pharmacy, online pharmacy, and retail pharmacy networks, and by implementing digital order management tools that increase transparency and responsiveness. Finally, align product development priorities with administration-route requirements for intramuscular versus intravenous use, ensuring compatibility with standard administration devices and training materials that reduce procedural variability. These measures will collectively enhance market credibility, reduce operational friction, and position organizations to respond rapidly to shifts in clinical practice and policy environments.

A rigorous triangulated research methodology integrating primary clinician and procurement interviews, regulatory review, literature validation, and supply-chain analysis for high-confidence insights

This research synthesis is founded on a triangulated methodology combining primary interviews, regulatory and clinical literature review, and supply-chain analysis to ensure reliable and actionable insights. Primary research included structured interviews with clinicians, hospital procurement officers, pharmacy directors, and supply-chain managers to capture real-world usage patterns, procurement constraints, and clinical preferences across diagnostic and therapeutic applications. These qualitative inputs were cross-referenced with regulatory documentation and product labeling to verify safety, administration-route guidance, and packaging constraints.

Complementary secondary research encompassed peer-reviewed clinical studies, procedural guidelines, and public regulatory filings to validate clinical use cases and to identify prevailing standards for sterility and labeling. Supply-chain mapping assessed manufacturing footprints, sterile-filling capabilities, packaging suppliers, and distribution pathways to identify common bottlenecks and resilience measures. Where appropriate, findings were corroborated through follow-up validation interviews and document reviews to ensure consistency and to reduce the risk of single-source bias. Together, these methods provide a robust foundation for the insights and recommendations presented, emphasizing transparency, reproducibility, and relevance to decision-makers across clinical, commercial, and procurement functions.

A succinct concluding synthesis emphasizing strategic priorities for manufacturing quality, clinical evidence, packaging innovation, and resilient distribution to support sustained adoption

In conclusion, iodized oil injection remains a clinically valuable and operationally nuanced product category that is adapting to new expectations for safety, evidence, and supply resilience. Its dual role in diagnostic imaging and targeted therapeutic delivery demands tailored formulation, packaging, and administration strategies to meet the needs of diverse clinical settings. The convergence of advanced imaging capabilities, stricter regulatory oversight, and evolving distribution models has elevated the importance of robust manufacturing practices, regionally attuned commercialization tactics, and proactive risk mitigation in procurement.

Moving forward, stakeholders who invest selectively in sterile manufacturing capacity, embrace packaging innovations that streamline procedural workflows, and generate targeted clinical evidence will be better positioned to meet clinician and purchaser expectations. At the same time, organizations that diversify distribution channels and prepare contingency sourcing plans will reduce exposure to policy and trade-related disruptions. Taken together, these strategic priorities form a coherent pathway for sustaining product availability, improving patient outcomes, and supporting long-term adoption across hospitals, diagnostic centers, clinics, and ambulatory care environments.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Iodized Oil Injection Market, by Administration Route

  • 8.1. Intramuscular
  • 8.2. Intravenous

9. Iodized Oil Injection Market, by Product Variant

  • 9.1. Multi Dose
  • 9.2. Single Dose

10. Iodized Oil Injection Market, by Packaging

  • 10.1. Prefilled Syringe
  • 10.2. Vial

11. Iodized Oil Injection Market, by Application

  • 11.1. Diagnostic
    • 11.1.1. Hepatic Imaging
    • 11.1.2. Lymphatic Imaging
  • 11.2. Therapeutic
    • 11.2.1. Hepatic Treatment
    • 11.2.2. Lymphatic Treatment

12. Iodized Oil Injection Market, by End User

  • 12.1. Ambulatory Care Centers
  • 12.2. Clinics
  • 12.3. Diagnostic Centers
  • 12.4. Hospitals

13. Iodized Oil Injection Market, by Distribution Channel

  • 13.1. Hospital Pharmacy
  • 13.2. Online Pharmacy
  • 13.3. Retail Pharmacy

14. Iodized Oil Injection Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Iodized Oil Injection Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Iodized Oil Injection Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Iodized Oil Injection Market

18. China Iodized Oil Injection Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Biophore India Pharmaceuticals Pvt. Ltd.
  • 19.6. BOC Sciences
  • 19.7. DVM Global Exports LLP
  • 19.8. Flagship Biotech International Pvt. Ltd.
  • 19.9. Fujifilm Toyama Chemical
  • 19.10. GE Healthcare
  • 19.11. Glowria Lifecare
  • 19.12. Guerbet
  • 19.13. Infinium Pharmachem Limited
  • 19.14. Jiangsu Hengrui Pharmaceuticals
  • 19.15. Shanghai Acebright Pharmaceuticals
  • 19.16. Shanghai Wonder Pharmaceutical
  • 19.17. Shanghai Zhongxi Sunve Pharmaceutical
  • 19.18. Teva Pharmaceutical Industries

LIST OF FIGURES

  • FIGURE 1. GLOBAL IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IODIZED OIL INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IODIZED OIL INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY MULTI DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY SINGLE DOSE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HEPATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY LYMPHATIC TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. MIDDLE EAST IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. GCC IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GCC IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 152. GCC IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 153. GCC IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 154. GCC IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 155. GCC IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 156. GCC IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 157. GCC IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. GCC IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. G7 IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 178. G7 IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 179. G7 IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 180. G7 IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 181. G7 IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. G7 IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 183. G7 IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 184. G7 IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. G7 IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. NATO IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. NATO IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 188. NATO IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 189. NATO IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 190. NATO IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. NATO IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 192. NATO IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 193. NATO IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. NATO IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. GLOBAL IODIZED OIL INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 197. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA IODIZED OIL INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA IODIZED OIL INJECTION MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA IODIZED OIL INJECTION MARKET SIZE, BY PRODUCT VARIANT, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA IODIZED OIL INJECTION MARKET SIZE, BY PACKAGING, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA IODIZED OIL INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA IODIZED OIL INJECTION MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA IODIZED OIL INJECTION MARKET SIZE, BY THERAPEUTIC, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA IODIZED OIL INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA IODIZED OIL INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)